Il-yang Makes Licensing Agreement for Grupo Uriach's Rupafin

Published: 2005-04-11 06:57:00

Updated: 2005-04-11 06:57:00

Il-yang Pharmaceutical Co. announced last week that the company signed an exclusive domestic licensing agreement for Rupafin (rupatadine fumarate), a novel antihistamine agent for the management of diseases with allergic inflammatory conditions, such as seasonal and perennial rhinitis.

Develop...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK